Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research report issued on Saturday. The brokerage set a “hold” rating on the stock.

A number of other research analysts also recently commented on the stock. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Price Performance

NYSE:CTLT opened at $63.48 on Friday. Catalent has a 52-week low of $41.15 and a 52-week high of $63.50. The company has a market cap of $11.52 billion, a P/E ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The stock’s 50-day simple moving average is $61.27 and its 200 day simple moving average is $59.84.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.10) EPS. As a group, sell-side analysts forecast that Catalent will post 0.78 EPS for the current fiscal year.

Insider Activity at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.31% of the stock is owned by company insiders.

Hedge Funds Weigh In On Catalent

Hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group bought a new stake in shares of Catalent during the 3rd quarter valued at $31,000. Sentry Investment Management LLC bought a new stake in Catalent during the third quarter worth about $53,000. Longfellow Investment Management Co. LLC grew its stake in Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its holdings in Catalent by 57.5% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after buying an additional 431 shares during the period. Finally, Intact Investment Management Inc. acquired a new position in shares of Catalent in the 3rd quarter valued at approximately $73,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.